BC
Metagenomi Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MGX-001 | Severe Hypertriglyceridemia (via APOC3 knockout) | Preclinical |
| Type V-K CAST System | Site-specific integration of therapeutic transgenes (e.g., Factor VIII for Hemophilia) | Preclinical |
| Ultra-Compact Type V Nuclease | In vivo genome editing (all-in-one AAV delivery) | Research |
| Compact Type II CRISPR System | CNS gene knockdown via AAV delivery | Research |
| Metagenomics-derived Base Editor | Human therapeutic applications | Research |
| Engineered Adenine Base Editors | Not specified | Research |
Leadership Team at Metagenomi
JI
Jian Irish, PhD, MBA
President and CEO
PW
Pamela Wapnick, MBA
CFO
MW
Matthew Wein, JD
General Counsel, Compliance Officer, Head of BD & L & Corporate Secretary
AB
Alan Brooks, PhD
SVP, Research
KK
Katalin Kauser, PhD, MD, Sc.D
SVP, Translational Biology
ML
Mark Leonard, PhD
SVP, Technical Operations
KS
Kapil Saxena, MD, MS
VP, Clinical Development
WD
Willard Dere, MD
Professor Emeritus, Internal Medicine, University of Utah (Board of Directors)
EB
Eric Bjerkholt, MBA
CFO of Mirum Pharmaceuticals, Inc. (Board of Directors)
JE
Juergen Eckhardt, MD, MBA
EVP, Head of Business Development & Licensing (BD & L) at Bayer, and Head of Leaps by Bayer (Board of Directors)